Valuation: Moderna, Inc.

Market Cap 29.28B 25.68B 23.71B 21.91B 41.53B 2,804B 42.36B 285B 111B 1,372B 110B 108B 4,763B P/E 2026 *
-8.52x
P/E 2027 * -15.5x
Enterprise Value 25.88B 22.7B 20.95B 19.36B 36.7B 2,478B 37.44B 252B 97.88B 1,213B 97.18B 95.05B 4,209B EV / Sales 2026 *
12.4x
EV / Sales 2027 * 10.7x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-7.48%
1 week+1.79%
Current month+5.38%
1 month+55.04%
3 months+41.65%
6 months+117.96%
Current year+150.25%
1 week 73.34
Extreme 73.3401
85.6
1 month 45.67
Extreme 45.67
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
07-05Free

Executive/Senior Manager

57,022 0.0144%
07-02Fiscal year

Chief Financial Officer

3,607 0.0009%
06-15Fiscal year

Chairperson

160,008 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
-7.48%+1.79%+126.80%-37.92% 29.28B
-1.97%+6.11%+21.02%-4.27% 67.44B
+0.72%-5.33%+47.09%+219.35% 53.98B
-4.15%+36.30%+36.30%+36.30% 41.77B
+0.99%+6.61%-48.49%-52.47% 41.15B
-2.60%-4.47%+49.01%-27.16% 29.58B
-0.67%+3.03%+73.28%+88.92% 23.43B
+0.17%+1.17%+4.98%+190.25% 19.11B
+0.46%-0.83%+67.70%+132.91% 16.82B
+0.54%+5.11%+81.36%+363.77% 15.36B
Average -0.35%+2.05%+45.91%+90.97% 33.79B
Weighted average by Cap. -1.06%+1.69%+38.01%+66.69%

Financials

2026 *2027 *
Net sales 2.09B 1.84B 1.7B 1.57B 2.97B 200B 3.03B 20.38B 7.92B 98.1B 7.86B 7.69B 341B 2.55B 2.24B 2.06B 1.91B 3.62B 244B 3.69B 24.82B 9.64B 119B 9.58B 9.37B 415B
Net income -3.41B -2.99B -2.76B -2.55B -4.84B -327B -4.93B -33.2B -12.9B -160B -12.81B -12.53B -555B -1.85B -1.62B -1.5B -1.38B -2.62B -177B -2.68B -18.01B -7B -86.7B -6.95B -6.8B -301B
Net Debt -3.41B -2.99B -2.76B -2.55B -4.83B -326B -4.93B -33.16B -12.88B -160B -12.79B -12.51B -554B -2.05B -1.8B -1.66B -1.54B -2.91B -197B -2.97B -19.99B -7.77B -96.21B -7.71B -7.54B -334B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
08/07/26 $73.80 -7.48% 6,581,662
07/07/26 $79.77 -2.48% 8,688,340
06/07/26 $81.80 +2.56% 17,296,875
02/07/26 $79.76 +10.01% 14,111,998
01/07/26 $72.50 +3.53% 9,275,292
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
73.80USD
Average target price
47.89USD
Spread / Average Target
-35.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock